In May 2015, we warned about rich valuations for small cap Biotech stocks and looked at various ways to evaluate those companies, as the majority have no approved drugs on the market, thus no revenue; therefore, valuing these companies using the conventional methodology is problematic.
Apr
05
2019
Small Cap Biotech Getting Pricey Again
tags
Small Cap Biotechnology Relative Strength Valuations Discounted Free Cash Flow Revenue Growth Leverage GS ScoresLogin
For full access, please enter your credentials.
Not a Subscriber?
If you are interested in subscribing to The Leuthold Group, contact us online or give us a call at 612-332-1567.
Contact UsAbout The Author
current issue
featured articles
recent tags
Japan
(47)
Factor Performance
(17)
Wealth Effect
(9)
Bank Lending
(1)
Dollar
(55)
Inflation
(584)
Resession
(1)
Time Cycles
(6)
Breakeven Rate
(1)
Oil
(48)
Value
(130)
Treasuries
(79)
Long T-Bonds
(24)
Active vs. Passive
(17)
Yield Curve
(85)
Economy
(282)
Federal Spending
(2)
Stock Market Performance
(1)
Fed Policy
(173)
Federal Debt/Deficit
(194)